Sequoia Financial Advisors LLC Sells 195 Shares of Illumina, Inc. (NASDAQ:ILMN)

Sequoia Financial Advisors LLC reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMNFree Report) by 7.3% in the third quarter, HoldingsChannel.com reports. The fund owned 2,490 shares of the life sciences company’s stock after selling 195 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Illumina were worth $342,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its stake in Illumina by 1.5% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 3,689 shares of the life sciences company’s stock valued at $746,000 after buying an additional 54 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of Illumina by 28.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 270 shares of the life sciences company’s stock valued at $94,000 after purchasing an additional 60 shares in the last quarter. Lido Advisors LLC grew its position in shares of Illumina by 3.7% during the 2nd quarter. Lido Advisors LLC now owns 1,752 shares of the life sciences company’s stock valued at $329,000 after purchasing an additional 63 shares in the last quarter. Independent Advisor Alliance grew its position in shares of Illumina by 4.6% during the 2nd quarter. Independent Advisor Alliance now owns 1,469 shares of the life sciences company’s stock valued at $275,000 after purchasing an additional 64 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its position in shares of Illumina by 1.6% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 4,078 shares of the life sciences company’s stock valued at $765,000 after purchasing an additional 64 shares in the last quarter. 92.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ILMN. Canaccord Genuity Group restated a “hold” rating and set a $120.00 price target (down from $210.00) on shares of Illumina in a research report on Friday, November 10th. Bank of America lowered shares of Illumina from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $140.00 to $100.00 in a research report on Tuesday, December 12th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Piper Sandler cut their target price on shares of Illumina from $200.00 to $190.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. Finally, Scotiabank upgraded shares of Illumina from a “sector perform” rating to a “sector outperform” rating and set a $185.00 target price for the company in a research report on Monday, December 18th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $166.95.

Read Our Latest Stock Analysis on Illumina

Illumina Stock Performance

Illumina stock opened at $137.84 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.69 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $21.89 billion, a PE ratio of -18.78, a P/E/G ratio of 24.83 and a beta of 1.22. The firm has a fifty day simple moving average of $135.24 and a two-hundred day simple moving average of $137.96. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $238.55.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.15%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.14 earnings per share. Research analysts expect that Illumina, Inc. will post 1.03 EPS for the current year.

Illumina Company Profile

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.